piperacillin + tazobactam


Alkem Lab


Getz Bros
Concise Prescribing Info
Piperacillin Na 4 g, tazobactam Na 500 mg
Moderate to severe infections including appendicitis & peritonitis, uncomplicated & complicated skin & skin structure infections, postpartum endometritis or pelvic inflammatory disease, community-acquired & nosocomial pneumonia.
Dosage/Direction for Use
IV infusion Adult 3.375 g 6 hrly. Total daily dose: 13.5 g (piperacillin 12 g/tazobactam 1.5 g). Nosocomial pneumonia Initially 4.5 g 6 hrly w/ an aminoglycoside for 7-14 days. Continue treatment w/ aminoglycoside in patients from whom P. aeruginosa is isolated.
Special Precautions
Discontinue use if bleeding manifestations occur. Neuromuscular excitability or convulsions in high doses particularly in the presence of renal failure. Patients requiring restricted salt intake. Hypokalemia in patients w/ low K reserves & those receiving cytotoxic therapy or diuretics. Increased incidence of fever & rash in cystic fibrosis patients. Patients w/ CrCl ≤40 mL/min & undergoing dialysis (hemodialysis & CAPD). Periodic assessment of hematopoietic function especially in prolonged use (≥21 days). Pregnancy & lactation. Childn. Elderly.
Adverse Reactions
Decreased Hb & hematocrit, thrombocytopenia, increased platelet count, eosinophilia, leukopenia, neutropenia; +ve direct Coombs' test, prolonged partial prothrombin time & partial thromboplastin time; transient elevations of AST (SGOT), ALT (SGPT), alkaline phosphatase, bilirubin; increased serum creatinine, BUN; proteinuria, hematuria, pyuria; abnormalities in electrolytes, hyperglycemia, decreased protein or albumin & blood glucose, increased γ-glutamyltransferase, hypokalemia, prolonged bleeding time. Hepatitis, cholestatic jaundice; hemolytic anemia, anemia, thrombocytosis, agranulocytosis; hpersensitivity & anaphylactic/anaphylactoid reactions (including shock); candidal superinfections; nephritis, renal failure; erythema multiforme, Stevens-Johnson syndrome & toxic epidermal necrolysis.
Drug Interactions
Inactivation of aminoglycosides. Decreased AUC, renal clearance & urinary recovery of tobramycin. False +ve reaction for urine glucose tests.
MIMS Class
ATC Classification
J01CR05 - piperacillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.
Pipzo powd for inj 4.5 g
1's (P1,050/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in